

State Corporation Commission

2019 Fiscal Impact Statement

1. Bill Number: SB1010

House of Origin ☒ Introduced ☐ Substitute ☐ Engrossed

Second House ☐ In Committee ☐ Substitute ☐ Enrolled

2. Patron: Black

3. Committee: Commerce and Labor

4. Title: Health insurance; coverage for Lyme disease therapy.

5. Summary: Requires health insurers, corporations providing healthcare coverage subscription contracts, and health maintenance organizations, whose policy, contract, or plan includes coverage for prescription drugs, to provide coverage for long-term antibiotic therapy for a patient with Lyme disease when determined to be medically necessary and ordered by a licensed physician after making a thorough evaluation of the patient's symptoms, diagnostic test results, or response to treatment. The measure applies to policies, contracts, and plans delivered, issued for delivery, or renewed on or after January 1, 2020.

6. Budget amendment necessary: No

7. Fiscal Impact Estimates: No Fiscal Impact on the State Corporation Commission

8. Fiscal Implications: None on the State Corporation Commission

9. Specific agency or political subdivisions affected: State Corporation Commission Bureau of Insurance

10. Technical amendment necessary: No

11. Other comments: Senate Bill 1010 proposes a new health insurance mandate for coverage of long-term antibiotic therapy for a patient with Lyme disease. Federal rules require that if a benefit is required by a state, other than for purposes of compliance with federal requirements, the state benefit is considered an addition to the Essential Health Benefits, and the state may be required to defray the cost of the additional requirement (45 CFR 155.170).

Date: 01/24/19/V. Tompkins